Surgical resection and adjuvant chemotherapy are the only treatment modalities for localized colorectal cancer that can obtain a "cure." The goal in surgically treating primary colorectal cancer is complete tumor removal along with dissection of systematic D3 lymph nodes. Adjuvant treatment controls recurrence and improves the prognosis of patients after they undergo R0 resection. Various clinical studies have promoted the gradual spread and clinical use of new surgical approaches such as laparoscopic surgery, robotic surgery, and transanal total mesorectal excision (TaTME).
| INTRODUC TI ON
According to the Vital Statistics of Japan, the number of deaths from colorectal cancer in Japan has continued to increase and, in 2016, it exceeded 50 000. 1 The basis of surgical treatment for colorectal cancer has continued to be primary resection with lymph node dissection. However, new approaches such as sphincter preservation surgery, transanal total mesorectal excision (TaTME), robotic surgery, and laparoscopic surgery have been spreading.
Important outcomes from the Japan Clinical Oncology Group (JCOG) 0404 trial were published indicating that laparoscopic surgery could be an acceptable option for patients with stage II or III colon cancer. Herein, we review and summarize the results of laparoscopic surgery and new approaches such as robotic surgery and TaTME.
The benefit of adjuvant chemotherapy has been confirmed in curatively resected stage III colon cancer, and it is now a standard treatment strategy in the guidelines of the Japanese Society for
Cancer of the Colon and Rectum (JSCCR). 2 The standard adjuvant chemotherapy regimen for colon cancer has been improved based on the findings from several large clinical trials. Ever since the significant benefit of adding oxaliplatin was proved, 3, 4 creating other effective regimens has been difficult because several trials showed that no additional benefit was gained by adding bevacizumab or cetuximab. [5] [6] [7] Thus, the prolonged neuropathy induced by oxaliplatin has emerged as a critical issue, and several prospective trials were conducted to test reductions in the duration of oxaliplatin treatment. 8 A prospective, pre-planned pooled analysis of six concurrently conducted randomized phase III trials (IDEA collaboration), including the ACHIEVE trial, was performed to evaluate the non-inferiority of 3 vs 6 months of adjuvant FOLFOX/ XELOX therapy. Although this study produced negative results, the authors suggested the possibility of adjusting the duration of adjuvant chemotherapy for stage III colon cancer according to the patient's risk and regimen and indicated the increasing importance of personalized medicine.
| G ENER AL PRIN CIPLE S OF RE S EC TI ON FOR COLOREC TAL C AN CER
Surgical resection of primary colon cancer is performed to completely remove the tumor, major vascular pedicles, and lymphatic drainage basin of the affected colonic and rectal segment and is achievable through an open or laparoscopic approach. However, the same principles of resection with lymph node dissection applicable to open surgery are also applicable to the laparoscopic approach.
Although the concept of complete mesocolic excision (CME)
has begun to emerge in recent years, 9 Japanese surgeons are already performing D3 lymph node dissection. Japanese D3 dissection and the current standard procedure of CME with central vascular ligation performed in the USA and Europe are almost identical although the resected colon is left slightly shorter following the Japanese D3 procedure. Theoretically, although the procedures should be equivalent because the principles are the same, a 2012 study 9 showed CME with central vascular ligation
and Japanese D3 dissection to be superior to the procedure used in previously reported cases.
Additionally, the Japanese specific lymph node dissection is pelvic lateral lymph node dissection, which is considered a distant metastasis in Western countries. Lateral lymph node dissection is indicated when the lower border of the tumor is located distal to the peritoneal reflection and the tumor has invaded beyond the muscularis propria. Prophylactic lateral lymph node dissection has a weak recommendation in the JSCCR guideline. 2 were analyzed from seven published randomized trials comprising 1536 patients in one meta-analysis and four trials with an endpoint of survival that enrolled more than 150 patients in the other.
| G U IDELINE S FOR COLOREC TAL C AN CER
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Both concluded that laparoscopic colectomy provides several on- undergoing the laparoscopic approach were more frequently administered adjuvant chemotherapy than those undergoing open colectomy (72% vs 67%). 27 Because adjuvant chemotherapy is typically started only after recovery from surgery, laparoscopy might result in fewer complications and faster postoperative recovery. The rates of macroscopic completeness of resection (88% vs 92%) and positive (<2 mm) circumferential resection margin (10% vs 10%)
| OPEN VS L APAROSCOPI C REC TAL RE S EC TI ON
were similar between the two groups, as were the 3-year rates of locoregional recurrence and survival. 29 In the COREAN South Korean trial, 340 patients with mid-to-low rectal cancer were randomly assigned to undergo laparoscopic or open surgery after preoperative chemoradiation therapy. 30 There were no significant differences in involvement of the circumferential resection margin, macroscopic quality of the total mesorectal excision specimen, number of harvested lymph nodes, or perioperative morbidity between the two groups. The 3-year rates of DFS for the open and laparoscopic surgery groups were similar (72.5% vs 79.2%). 31 In the ACOSOG Z6051 trial, which was designed to investigate non-inferiority of the laparoscopic approach, 486 patients with stage II or III rectal cancer within 12 cm of the anal verge were randomly assigned to
undergo laparoscopic or open surgery after neoadjuvant therapy. 32 The primary endpoint was successful pathologic outcome, defined as simultaneous achievement of a >1-mm distal margin, >1-mm circumferential radial margin, and adequate total mesorectal excision. In a follow-up study, comparable rates were reported for 2-year These studies are summarized in Table 2 .
A systematic review and meta-analysis of randomized trials that including the four above-mentioned studies concluded that, for rectal cancer, a higher rate of "noncomplete" (composite of incomplete and near-complete) total mesorectal excision was achieved with laparoscopic surgery than with open surgery (13.2% vs 10.4%).
However, the rates of circumferential and distal margin involvement, mean numbers of lymph nodes retrieved, and mean distances to radial and distal margins were similar between the two techniques. 35 
| ROBOTI C SURG ERY
Robot-assisted surgery is an emerging technology combining the advantages of the laparoscopic approach (e.g. faster recovery with less postoperative pain) with those of open surgery (e.g. high-quality three-dimensional view and restoration of the eye-hand-target axis). [36] [37] [38] [39] As indicated by small retrospective reviews, in terms of lymph node harvesting and maintenance of negative radial margins, robot-assisted total mesorectal excision is feasible, safe, and as efficacious as the open and laparoscopic approaches.
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Furthermore, three separate case-matched analyses of patients undergoing robot-assisted, laparoscopic, or open resection of midor low-rectal cancers found no significant differences in oncologic outcomes. [43] [44] [45] However, robot-assisted surgery comes with the disadvantages of high cost and long set-up and procedure times. The ROLARR trial showed that operative time was longer and cost was higher when robotic-assisted laparoscopic rectal surgery was performed by surgeons with varying degrees of experience with robotic surgery, and it offered no incremental benefit over conventional laparoscopic surgery. Of note, the issue of oncologic equivalency of robotic-assisted laparoscopic surgery to conventional or open rectal surgery was not addressed in the published data from the ROLARR trial.
A systematic review and meta-analysis performed in 2018 of five trials, including ROLARR, comparing robotic-assisted resection for rectal cancer with that of conventional laparoscopy found similar perioperative outcomes regarding mortality, rate of circumferential margin involvement, and number of lymph nodes harvested. 48 Conversion from robotic surgery to open surgery was less likely (7.5% vs 12.9%), but robotic surgery took slightly longer than conventional laparoscopic surgery (mean difference 38 minutes).
| TaTME
In centers with experienced surgeons, TME has also been attempted transanally for distal rectal tumors, particularly in obese men with a narrow pelvis. [49] [50] [51] Because the distal margin can be assessed precisely from the beginning of the procedure, the resection margins can be defined more clearly in TaTME than in standard transabdominal TME. A randomized trial of patients with low rectal cancer (<6 cm from anal verge) that compared TaTME with standard TME showed a lower rate of positive circumferential resection margin for TaTME (4% vs 18%), with other outcomes being comparable between the groups. 52 Other studies following up patients for up to 29 months showed comparable rates of local recurrence and survival between TaTME and standard TME. 50, 53 However, long-term oncologic outcomes of TaTME have not been reported yet. Additionally, iatrogenic urethral injury has been reported with TaTME in men. 54 Presently, TaTME
remains an investigational technique that should only be performed by experienced surgeons in high-volume centers. For most patients with rectal cancer, transabdominal TME remains the standard treatment of choice. improved therapeutic ratio. 55 The benefit offered by oral fluoropyrimidines was investigated in a meta-analysis of individual data from five Japanese trials comprising 5232 patients with resected stage I, II, or III colon cancer who were randomly assigned to receive adjuvant oral fluoropyrimidines (FU, UFT, or hexacarbonyl FU) or undergo observation only. 56 Overall, oral therapy reduced the risk of recurrence by 11% and death by 15%. However, an absolute survival benefit of only 2.5% was achieved for patients with stage III disease.
| ADJ U VANT CHEMOTHER APY FOR RE S EC TED S TAG E III COLOREC TAL C AN CER
More recent trials suggest that the benefit achievable with either capecitabine or UFT is at least equivalent to that of FU/ LV administered by intravenous bolus. Two randomized trials of oral capecitabine compared with intravenous fluoropyrimidines showed equivalent rates of 6-month DFS. 57, 58 In the earlier trial, the European/Canadian Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) study, 1987 patients with resected stage III colon cancer
were randomly assigned to 6 months of capecitabine alone. 57 The trial was statistically powered to show therapeutic equivalence, and DFS was the primary endpoint.
Six months of UFT plus LV is a standard approach for adjuvant chemotherapy of stage III colon cancer in Japan. 35, 59, 60 The NSABP C-06 trial showed the comparative efficacy of UFT plus LV compared with parenteral FU/LV in non-Asian populations comprising 1608 patients with resected stage II or III colon cancer who were randomly assigned to a weekly bolus of FU with high-dose LV. 61 The 5-year rates of DFS or OS were not significantly different. A similar conclusion was reached in the JCOG0205 phase III trial of patients with stage III disease only. 60 In a Japanese trial of 1535 patients with resected stage III colon cancer, the utility of S-1 for adjuvant treatment of the cancer was determined by directly comparing S1 with UFT plus LV. 62 S-1 was found to be non-inferior to UFT + LV (hazard ratio [HR] for DFS, 0.85; 95%
CI, 0.70-1.03), and the rates of adverse events were comparable.
However, S-1 was found to be inferior to capecitabine monotherapy in the JCOG0910 non-inferiority multicenter randomized trial. 63 At present, we should make clinical decision about adjuvant chemotherapy taking into account patient characteristics, values, and preferences, and the potential for benefit and risks of adverse events associated with treatment.
| DUR ATI ON OF ADJ U VANT CHEMOTHER APY
The optimal duration of adjuvant oxaliplatin chemotherapy for should undergo 6 months of adjuvant oxaliplatin-based chemotherapy, whereas lower-risk patients can undergo either 3 or 6 months of therapy. 65 The ASCO expert panel recommended a shared decision-making approach that takes patient characteristics, values, and preferences, and the potential for benefit and risks of harm as- In Japan, the JSCCR has developed a nomogram to calculate risk of recurrence after curative resection that includes data on age, gender, tumor location, stage, and preoperative tumor markers from 19 institutions. This is expected to be an important information tool for use in personalized medicine. Additionally, a report based on data from NSABP C-07 suggested that use of the Oncotype DX colon cancer assay for genomic profiling might improve risk prognostication in stage III disease and better clarify the absolute benefit that might be achieved by adding oxaliplatin to the therapy of these patients. 67 High Recurrence Score values indicated a higher absolute benefit from oxaliplatin. However, even among the patients with the highest risk, stage IIIC disease, the absolute difference in the risk of recurrence at 5 years by adding oxaliplatin was small in the patients with a low Recurrence Score (FU treated: 41%; 95% CI, 28%-57%, vs oxaliplatin treated: 38%;
95% CI, 23%-58%) vs those with a high Recurrence Score (FU treated: 67%; 95% CI, 52%-82% vs oxaliplatin treated: 59%; 95% CI, 42%-76%). Furthermore, the estimates are quite imprecise and may not be clinically meaningful. In recent years, the 12-gene
Oncotype DX assay, which is now available to Japanese patients, 68 might allow the choice of agent and regimen according to the risk of recurrence. At present, we should make clinical decisions about adjuvant chemotherapy by taking into account patient characteristics, values, and preferences, and the potential for benefit and risks of adverse events associated with treatment. 
| CON CLUS ION
